作者曾报告过年轻男性骨质疏松症患者体内血清胰岛素样生长因子-1(IGF-1)的含量偏低。许多体外研究证明 IGF-1可促进成骨细胞的合成代谢。从而提示 IGF-1不仅在骨质疏松症病理生理方面起作用,而且还可以用它来治疗骨质疏松症。作者对一位59岁男性特发性骨质疏松症患者,进行了每天一次皮下注射160μg/kg 的重组人 IGF-1共7天的试验治疗。观察了患者体内骨代谢的若干血、尿 The authors have reported low levels of serum insulin-like growth factor-1 (IGF-1) in young men with osteoporosis. Many in vitro studies demonstrate that IGF-1 can promote osteoblast anabolism. Thus suggesting that IGF-1 not only plays a role in the pathophysiology of osteoporosis, but also can be used to treat osteoporosis. The authors conducted a pilot study of a 59-year-old male idiopathic osteoporosis patient who had received a daily subcutaneous injection of 160 μg / kg recombinant human IGF-1 for 7 days. A number of blood and urine were observed in patients with bone metabolism